Endurance exercise such as walking has been shown to help breast cancer survivors maintain their energy and quality of life while they are receiving chemotherapy, but there have not been any studies on weight training. In this study, the researchers want to determine if a combined program of endurance and weight training exercises is better than a standard amount of endurance exercise or even a higher amount of endurance exercise in breast cancer survivors receiving chemotherapy. The study will be an experimental design in which the researchers have breast cancer survivors participate in each of the three different exercise programs. The researchers'''' main interest is in quality of life, which they will measure before and after the exercise programs by asking participants how they feel on various rating scales. The researchers will also measure their aerobic fitness on a treadmill and how strong they are by having them lift weights.

Condition	Intervention	Phase
Breast Cancer	Behavior: Physical exercise	Phase III

Further study details as provided by Alberta Cancer Board:

Primary Outcomes: Quality of life
Secondary Outcomes: Cardiovascular fitness; Muscular strength; Body composition; Treatment completion rates; Adverse events
Expected Total Enrollment:  240

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Female

Criteria

Inclusion Criteria:

• Are diagnosed with stage I-IIIA breast cancer
• Are scheduled to receive neoadjuvant or adjuvant chemotherapy
• Have not received previous chemotherapy
• Did not receive transabdominal rectus abdominis muscle (TRAM) reconstructive therapy
• Are 18 years or older
• Received approval from their treating oncologist
• Do not have uncontrolled hypertension, cardiac illness or psychiatric condition
• Are not pregnant
• Are able to understand and provide written consent in English or French
• Have no major contraindications to exercise based on maximal aerobic and strength tests

Please refer to this study by ClinicalTrials.gov identifier  NCT00249015

Kerry Courneya, PhD      780-432-2829    kerry.courneya@ualberta.ca

Canada, Alberta
      Cross Cancer Institute, Edmonton,  Alberta,  T6G 1Z2,  Canada

Study chairs or principal investigators

Kerry Courneya, PhD,  Principal Investigator,  Alberta Cancer Board   

Study ID Numbers:  BR-01-0080
Last Updated:  December 8, 2005
Record first received:  November 4, 2005
ClinicalTrials.gov Identifier:  NCT00249015
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2006-01-10